{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:04:30Z","timestamp":1776405870663,"version":"3.51.2"},"reference-count":25,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":405,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015471","name":"Mater Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015471","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1111\/ajt.16628","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T05:01:08Z","timestamp":1620104468000},"page":"3465-3471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Successful treatment of Epstein\u2013Barr virus\u2013associated primary central nervous system lymphoma due to post-transplantation lymphoproliferative disorder, with ibrutinib and third-party Epstein\u2013Barr virus\u2013specific T cells"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0782-6951","authenticated-orcid":false,"given":"Soi C.","family":"Law","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanh","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kacey","family":"O\u2019Rourke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4982-525X","authenticated-orcid":false,"given":"Joshua W.D.","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2695-3849","authenticated-orcid":false,"given":"Jay","family":"Gunawardana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothy","family":"Loo-Oey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7201-5269","authenticated-orcid":false,"given":"Karolina","family":"Bednarska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6989-8424","authenticated-orcid":false,"given":"Lilia","family":"Merida de Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-8878","authenticated-orcid":false,"given":"Muhammed B.","family":"Sabdia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7980-8496","authenticated-orcid":false,"given":"Greg","family":"Hapgood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7849-7139","authenticated-orcid":false,"given":"Emily","family":"Blyth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leighton","family":"Clancy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5972-3711","authenticated-orcid":false,"given":"Stefanie","family":"Hennig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9009-9934","authenticated-orcid":false,"given":"Colm","family":"Keane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1000-5393","authenticated-orcid":false,"given":"Maher K.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1111\/ajt.16628_bib1","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/j.1600-6143.2011.03499.x","article-title":"Epstein-Barr Virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy","volume":"11","author":"Nourse","year":"2011","journal-title":"Am J Transplant."},{"issue":"6","key":"10.1111\/ajt.16628_bib2","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1111\/ajt.12211","article-title":"Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era","volume":"13","author":"Evens","year":"2013","journal-title":"Am J Transplant."},{"issue":"11","key":"10.1111\/ajt.16628_bib3","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1111\/ajt.12858","article-title":"A comprehensive analysis of the cellular and EBV-specific microRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors","volume":"14","author":"Fink","year":"2014","journal-title":"Am J Transplant."},{"issue":"11","key":"10.1111\/ajt.16628_bib4","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1182\/blood.2020008520","article-title":"EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity","volume":"137","author":"Gandhi","year":"2021","journal-title":"Blood."},{"issue":"2","key":"10.1111\/ajt.16628_bib5","first-page":"146","article-title":"Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes","volume":"1","author":"Nguyen-Van","year":"2011","journal-title":"Am J Blood Res."},{"issue":"22","key":"10.1111\/ajt.16628_bib6","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol."},{"issue":"3","key":"10.1111\/ajt.16628_bib7","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/ajh.22252","article-title":"Tumor-specific but not nonspecific cell-free circulating DNA can be used to monitor disease response in lymphoma","volume":"87","author":"Jones","year":"2012","journal-title":"Am J Hematol."},{"issue":"3","key":"10.1111\/ajt.16628_bib8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/ejh.13274","article-title":"The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma","volume":"103","author":"Keane","year":"2019","journal-title":"Eur J Haematol."},{"issue":"1\u20132","key":"10.1111\/ajt.16628_bib9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jviromet.2012.05.005","article-title":"Expression profiling of Epstein-Barr virus-encoded microRNAs from paraffin-embedded formalin-fixed primary epstein-barr virus-positive B-cell lymphoma samples","volume":"184","author":"Nourse","year":"2012","journal-title":"J Virol Methods."},{"issue":"5","key":"10.1111\/ajt.16628_bib10","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.bbmt.2017.12.802","article-title":"Ultra-sensitive droplet digital PCR for the assessment of microchimerism in cellular therapies","volume":"24","author":"Kliman","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"issue":"25","key":"10.1111\/ajt.16628_bib11","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood.2019000889","article-title":"EBV microRNA-BHRF1-2-5p targets the 3\u2019UTR of immune checkpoint ligands PD-L1 and PD-L2","volume":"134","author":"Cristino","year":"2019","journal-title":"Blood."},{"issue":"9","key":"10.1111\/ajt.16628_bib12","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1111\/ajt.16628_bib13","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell."},{"key":"10.1111\/ajt.16628_bib14","article-title":"Ibrutinib as a possible therapeutic strategy for epstein-barr virus-positive lymphoma\/leukemia","volume":"130","author":"Kotaki","year":"2017","journal-title":"Blood."},{"issue":"11","key":"10.1111\/ajt.16628_bib15","first-page":"2489","article-title":"The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma","volume":"6","author":"Kuo","year":"2016","journal-title":"Am J Cancer Res."},{"issue":"25","key":"10.1111\/ajt.16628_bib16","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1182\/blood-2016-06-715284","article-title":"Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT","volume":"128","author":"Ryan","year":"2016","journal-title":"Blood."},{"issue":"10","key":"10.1111\/ajt.16628_bib17","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.bbmt.2019.06.023","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy: 1-year update of a phase 1b\/2 study","volume":"25","author":"Waller","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"4","key":"10.1111\/ajt.16628_bib18","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1365-2141.2006.06482.x","article-title":"Epstein-barr virus T-cell immunity despite rituximab","volume":"136","author":"Nehring","year":"2007","journal-title":"Br J Haematol."},{"issue":"2","key":"10.1111\/ajt.16628_bib19","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30747-2","article-title":"Rituximab in patients with primary CNS lymphoma (HOVON 105\/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study","volume":"20","author":"Bromberg","year":"2019","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1111\/ajt.16628_bib20","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1016\/j.clml.2020.10.007","article-title":"Successful long-term ibrutinib treatment in a hemodialysis patient with leukemic nonnodal mantle cell lymphoma","volume":"21","author":"Yasuda","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"6","key":"10.1111\/ajt.16628_bib21","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/bjh.16946","article-title":"Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance\/MD Anderson Cancer Center experience","volume":"192","author":"Lewis","year":"2021","journal-title":"Br J Haematol."},{"issue":"18","key":"10.1111\/ajt.16628_bib22","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood.2020006449","article-title":"Zanubrutinib for the treatment of patients with Waldenstr\u00f6m macroglobulinemia: 3 years of follow-up","volume":"136","author":"Trotman","year":"2020","journal-title":"Blood."},{"issue":"6","key":"10.1111\/ajt.16628_bib23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.blre.2015.06.002","article-title":"Deregulated JAK\/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies","volume":"29","author":"Scott","year":"2015","journal-title":"Blood Rev."},{"issue":"5","key":"10.1111\/ajt.16628_bib24","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/j.1600-6143.2007.01796.x","article-title":"Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders","volume":"7","author":"Gandhi","year":"2007","journal-title":"Am J Transplant."},{"issue":"2","key":"10.1111\/ajt.16628_bib25","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1172\/JCI121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation","volume":"130","author":"Prockop","year":"2020","journal-title":"J Clin Invest."}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.16628","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajt.16628","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522087676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522087676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.16628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:34:53Z","timestamp":1761629693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522087676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1600613522087676"],"URL":"https:\/\/doi.org\/10.1111\/ajt.16628","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful treatment of Epstein\u2013Barr virus\u2013associated primary central nervous system lymphoma due to post-transplantation lymphoproliferative disorder, with ibrutinib and third-party Epstein\u2013Barr virus\u2013specific T cells","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.16628","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}